Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 5/20 | 0.63 |
| ▸ | GAA known ✓ | P10253 | 5/20 | 0.63 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.46 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.63 |
| ▸ | HPGD | P15428 | 6/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.63 |
| ▸ | CASP1 | P29466 | 2/20 | 0.63 |
| ▸ | CASP7 | P55210 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.47 |
| ▸ | IGLV6-57 | P01721 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL22611961 | 1.00 | ALDH1A1 (0.63) | ALDH1A1KDM4EHPGDGLAGAA | |
| Leucine SCHEMBL27779804 | 0.99 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDGLAGAA | |
| Leucine SCHEMBL19695473 | 0.99 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDGLAGAA | |
| Leucine SCHEMBL1776947 | 0.99 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDGLAGAA | |
| Serine SCHEMBL4186225 | 0.88 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDGLAGAA | |
| Aspartic Acid SCHEMBL7700638 | 0.88 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDGLAGAA | |
| Aspartic Acid SCHEMBL7700642 | 0.88 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDGLAGAA | |
| Asparagine SCHEMBL27896279 | 0.87 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDGLAGAA | |
| Asparagine SCHEMBL4176738 | 0.87 | ALDH1A1 (0.64) | ALDH1A1KDM4EHPGDGLAGAA | |
| Serine SCHEMBL6428011 | 0.87 | ALDH1A1 (0.68) | ALDH1A1KDM4EHPGDGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084308-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2024-03-14 | — | — | US | claimed |
| US-11834663-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2023-12-05 | — | — | US | claimed |
| US-20210340547-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2021-11-04 | — | — | US | claimed |
| US-11078488-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2021-08-03 | — | — | US | claimed |
| US-20200362354-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2020-11-19 | — | — | US | claimed |
| US-10787668-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2020-09-29 | — | — | US | claimed |
| EP-3328384-B1 | FIBROTIC TREATMENT | UNIV MONASH (AU) | 2020-07-29 | — | — | EP | claimed |
| US-10100311-B2 | Fibrotic treatment | MONASH UNIVERSITY (AU) | 2018-10-16 | — | — | US | claimed |
| US-20180223287-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2018-08-09 | — | — | US | claimed |
| EP-3328384-A1 | FIBROTIC TREATMENT | Monash University (AU) | 2018-06-06 | — | — | EP | claimed |
| WO-2017015720-A1 | FIBROTIC TREATMENT | MONASH UNIVERSITY (AU) | 2017-02-02 | — | — | WO | claimed |
| EP-1352083-B1 | COMPOSITIONS AND METHODS FOR DETECTING TARGET MICROORGANISMS IN A SAMPLE | BIOCONTROL SYSTEMS INC (US) | 2005-10-26 | — | — | EP | claimed |
| EP-0946746-B1 | METHOD AND MEDIA FOR THE DETECTION OF YEASTS AND/OR MOLDS IN A SAMPLE | BIOCONTROL SYSTEMS INC (US) | 2005-03-02 | — | — | EP | claimed |
| EP-1352083-A2 | COMPOSITIONS AND METHODS FOR DETECTING TARGET MICROORGANISMS IN A SAMPLE | BioControl Systems, Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020058298-A1 | Compositions and methods for detecting target microorganisms in a sample | BIOCONTROL SYSTEM, INC. (US) | 2002-05-16 | — | — | US | claimed |
| WO-2002018625-A2 | COMPOSITIONS AND METHODS FOR DETECTING TARGET MICROORGANISMS IN A SAMPLE | BIOCONTROL SYSTEMS, INC. (US) | 2002-03-07 | — | — | WO | claimed |
| US-6022698-A | Method and components for the detection of yeasts and/or molds in a sample | IDEXX LABORATORIES, INCORPORATED (US) | 2000-02-08 | — | — | US | claimed |
| EP-0946746-A1 | METHOD AND COMPONENTS FOR THE DETECTION OF YEASTS AND/OR MOLDS IN A SAMPLE | IDEXX LABORATORIES, INC. (US) | 1999-10-06 | — | — | EP | claimed |
| US-5854011-A | Method and components for the detection of yeasts and/or molds in a sample | IDEXX LABORATORIES INCORPORATED (US) | 1998-12-29 | — | — | US | claimed |
| WO-1998027223-A1 | METHOD AND COMPONENTS FOR THE DETECTION OF YEASTS AND/OR MOLDS IN A SAMPLE | IDEXX LABORATORIES, INCORPORATED (US) | 1998-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100311-B2 | Fibrotic treatment | ENPEP, IL4I1, LNPEP | GLA 1078/4885GAA 1458/4885MAOB 1975/4885 |
| US-10787668-B2 | Fibrotic treatment | ENPEP, IL4I1, LNPEP | GLA 1078/4885GAA 1458/4885MAOB 1975/4885 |
| US-20210340547-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | GLA 347/4885GAA 320/4885MAOB 2586/4885 |
| US-20200362354-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | GLA 347/4885GAA 320/4885MAOB 2586/4885 |
| US-20180223287-A1 | FIBROTIC TREATMENT | ENPEP, IL4I1, LNPEP | GLA 1078/4885GAA 1458/4885MAOB 1975/4885 |
| US-11834663-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | GLA 347/4885GAA 320/4885MAOB 2586/4885 |
| US-11078488-B2 | Fibrotic treatment | MMP1, ENPEP, RNPEP | GLA 347/4885GAA 320/4885MAOB 2586/4885 |
| US-20240084308-A1 | FIBROTIC TREATMENT | MMP1, ENPEP, RNPEP | GLA 347/4885GAA 320/4885MAOB 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.